单位：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China血液内科华中科技大学同济医学院附属同济医院[2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China[3]Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院放射科
General Program of the National
Natural Science Foundation of China (YC; 81570197) and the Youth
Science Fund Project of the National Natural Science Foundation of
China (NW; 81600120).
第一作者单位：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China[2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China[2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China
推荐引用方式(GB/T 7714)：
Xu Hao,Lv Qiuxia,Huang Liang,et al.Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma[J].CYTOTHERAPY.2023,25(2):185-191.doi:10.1016/j.jcyt.2022.10.001.
APA：
Xu Hao,Lv Qiuxia,Huang Liang,Cao Wenyue,Wang Jue...&Cao Yang.(2023).Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.CYTOTHERAPY,25,(2)
MLA：
Xu Hao,et al."Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma".CYTOTHERAPY 25..2(2023):185-191
